{"gene":"BCL9L","run_date":"2026-04-28T17:12:38","timeline":{"discoveries":[{"year":2004,"finding":"BCL9-2 (BCL9L) binds β-catenin and promotes nuclear β-catenin-dependent transcription, inducing epithelial-mesenchymal transition; this binding is modulated by phosphorylation of Tyr142 of β-catenin, which favors BCL9-2 binding and precludes interaction with α-catenin, thereby switching β-catenin from adhesive to transcriptional functions.","method":"RNA interference, co-immunoprecipitation, reporter assays, zebrafish epistasis (Wnt8 pathway), in vivo EMT assays","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (RNAi, Co-IP, in vivo epistasis), highly cited foundational paper","pmids":["15371335"],"is_preprint":false},{"year":2004,"finding":"BCL9L (B9L) interacts with the β-catenin–TCF complex and enhances its transactivation potential; B9L is required for elevated β-catenin–TCF-mediated transcription in colorectal tumor cells and for β-catenin-induced cellular transformation.","method":"Co-immunoprecipitation, luciferase reporter assays, siRNA knockdown, RK3E transformation assay","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP plus functional reporter and transformation assays","pmids":["15574752"],"is_preprint":false},{"year":2006,"finding":"BCL9-2 functionally replaces Drosophila Legless in Wg/Wnt signaling both in cultured mammalian cells and in vivo in Drosophila; this rescue activity requires the ability of BCL9-2 to bind Pygopus via its HD1 domain, and Tyr142 phosphorylation of β-catenin is not required for BCL9-2 binding or transcriptional activity.","method":"Drosophila genetic rescue assays, mammalian cell reporter assays, site-directed mutagenesis of Tyr142","journal":"Mechanisms of development","confidence":"High","confidence_rationale":"Tier 1–2 — mutagenesis combined with in vivo genetic rescue across two systems","pmids":["17113272"],"is_preprint":false},{"year":2010,"finding":"Conditional ablation of both Bcl9 and Bcl9l in mouse intestinal epithelium decreases expression of intestinal stem cell markers, impairs colon epithelium regeneration, and abolishes EMT and stem cell-like properties in adenocarcinomas, establishing Bcl9/Bcl9l as essential mediators of a Wnt-dependent subset of target genes controlling EMT and stemness.","method":"Conditional knockout mouse model, transcriptional profiling, immunohistochemistry, stem cell marker analysis","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 — clean conditional KO with defined cellular and transcriptional phenotype, replicated with Bcl9/Bcl9l double ablation","pmids":["20682801"],"is_preprint":false},{"year":2011,"finding":"BCL9-2 regulates expression of both β-catenin-dependent and β-catenin-independent target genes in intestinal epithelia; transgenic overexpression of BCL9-2 in the intestine of APCMin/+ mice accelerates adenoma formation and progression to invasive tumors.","method":"siRNA knockdown, transgenic mouse overexpression crossed with APCMin/+, gene expression analysis","journal":"Gastroenterology","confidence":"High","confidence_rationale":"Tier 2 — in vivo transgenic model with tumor phenotype plus siRNA mechanistic data","pmids":["21703997"],"is_preprint":false},{"year":2014,"finding":"BCL9-2 regulates estrogen receptor alpha (ERα) transcription independently of β-catenin by interacting with the transcription factor Sp1 at the proximal ESR1 gene promoter.","method":"Co-immunoprecipitation, chromatin immunoprecipitation, luciferase reporter assays, siRNA knockdown, transgenic mouse model","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 — Co-IP plus ChIP plus reporter assays in single lab","pmids":["25149534"],"is_preprint":false},{"year":2015,"finding":"WWOX interacts with BCL9-2 in the nucleus (co-localizing with β-catenin) and inhibits BCL9-2-dependent Wnt/β-catenin transcriptional activity by blocking the β-catenin–TCF1 interaction; HDAC3 associates with BCL9-2, promotes the WWOX–BCL9-2 interaction independently of its deacetylase activity, and enhances WWOX-mediated inhibition of BCL9-2.","method":"Co-immunoprecipitation, luciferase reporter assays, Xenopus secondary axis assay, confocal co-localization","journal":"Molecular cancer research","confidence":"Medium","confidence_rationale":"Tier 2 — multiple orthogonal methods (Co-IP, reporter, Xenopus in vivo assay) from single lab","pmids":["25678599"],"is_preprint":false},{"year":2016,"finding":"BCL9L knockdown in pancreatic cancer cells induces an epithelial phenotype (increased E-cadherin, membrane retention of β-catenin), impairs proliferation, migration and invasion, and significantly reduces liver metastasis in xenograft mouse models; BCL9L depletion prevents TGF-β-induced EMT.","method":"RNAi knockdown, xenograft mouse model, cell migration/invasion assays, immunofluorescence","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 — KD with multiple cellular phenotype readouts plus in vivo xenograft","pmids":["27713160"],"is_preprint":false},{"year":2017,"finding":"BCL9L loss-of-function (LOH and mutations in CRC) reduces basal caspase-2 levels and prevents caspase-2-mediated cleavage of MDM2 and BID, thereby promoting tolerance of chromosome missegregation events and aneuploidy propagation; this occurs independently of TP53 status.","method":"Genomic analysis of CRC, cell line knockdown, xenograft models, caspase-2 activity assays, protein cleavage assays","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 2 — multiple functional assays (caspase cleavage, in vivo xenograft, CIN phenotype) in a single rigorous study","pmids":["28073006"],"is_preprint":false},{"year":2021,"finding":"Conditional double knockout of Bcl9 and Bcl9l in the MMTV-PyMT breast cancer mouse model causes tumor cell death; disruption of the Bcl9/Bcl9l HD2 domain interaction with β-catenin (or the β-catenin D164A point mutation) reduces primary tumor growth, proliferation, invasion and lung metastasis; disruption of HD1-mediated binding to Pygopus has only moderate effects.","method":"Conditional knockout mouse model, domain-deletion mutants, point mutagenesis (D164A), tumor growth and metastasis assays","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1–2 — domain-specific mutagenesis combined with in vivo conditional KO and metastasis readouts","pmids":["34545187"],"is_preprint":false},{"year":2021,"finding":"BCL9/BCL9L promotes tumorigenicity in TNBC through both Wnt and TGF-β pathways; BCL9/BCL9L inhibits infiltration of CD8+ T cells in the tumor microenvironment, and pharmacological inhibition with hsBCL9CT-24 promotes cytotoxic T cell infiltration and reduces Treg cells.","method":"Genetic knockdown, pharmacological inhibitor, tumor microenvironment immune profiling, co-culture assays","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — KD plus pharmacological inhibition with defined immune phenotype, single lab","pmids":["33767438"],"is_preprint":false},{"year":2024,"finding":"Targeting BCL9/BCL9L (pharmacological inhibitor hsBCL9z96 or genetic knockout) promotes antigen presentation in tumors by increasing conventional type 1 dendritic cell (cDC1) activation and tumor infiltration via the XCL1–XCR1 axis; Bcl9/Bcl9l-deficient cDC1 show superior antigen presentation through NF-κB/IRF1 signaling.","method":"Bcl9/Bcl9l knockout mice, pharmacological inhibitor, single-cell transcriptomics, CD8+ T cell functional assays","journal":"Signal transduction and targeted therapy","confidence":"Medium","confidence_rationale":"Tier 2 — KO mouse plus pharmacological inhibition plus scRNA-seq mechanistic pathway identification","pmids":["38811552"],"is_preprint":false}],"current_model":"BCL9L (BCL9-2/B9L) is a nuclear transcriptional co-activator that binds β-catenin (via its HD2 domain, enhanced by Tyr142 phosphorylation of β-catenin) and Pygopus (via its HD1 domain) to amplify Wnt/β-catenin target gene transcription, promotes epithelial-to-mesenchymal transition and intestinal stem cell maintenance, regulates ERα transcription independently of β-catenin through Sp1 interaction, controls caspase-2 levels to modulate aneuploidy tolerance, and shapes antitumor immunity by restraining cDC1 activation and CD8+ T cell infiltration."},"narrative":{"teleology":[{"year":2004,"claim":"Identification of BCL9L as a β-catenin-binding co-activator established its role in Wnt-dependent transcription and revealed that Tyr142 phosphorylation of β-catenin switches it from adhesive to transcriptional functions by favoring BCL9L recruitment.","evidence":"Co-IP, RNAi, reporter assays, and zebrafish Wnt8 epistasis in mammalian cells and zebrafish","pmids":["15371335","15574752"],"confidence":"High","gaps":["Whether Tyr142 phosphorylation is required for BCL9L binding was subsequently contested","Relative contributions of BCL9L versus BCL9 were not delineated"]},{"year":2006,"claim":"Cross-species rescue showed BCL9L functionally replaces Drosophila Legless in Wg/Wnt signaling and that HD1-mediated Pygopus binding is essential, while Tyr142 phosphorylation of β-catenin proved dispensable for BCL9L activity.","evidence":"Drosophila genetic rescue, mammalian reporter assays, Tyr142 site-directed mutagenesis","pmids":["17113272"],"confidence":"High","gaps":["Structural basis of HD1–Pygopus and HD2–β-catenin interfaces not resolved","In vivo mammalian requirement for BCL9L not yet tested"]},{"year":2010,"claim":"Conditional ablation of Bcl9 and Bcl9l in mouse intestinal epithelium demonstrated their non-redundant requirement for intestinal stem cell gene expression, colon regeneration, and EMT/stemness in adenocarcinomas.","evidence":"Conditional double knockout mouse, transcriptional profiling, immunohistochemistry","pmids":["20682801"],"confidence":"High","gaps":["Individual contribution of Bcl9l versus Bcl9 in the intestine not separated","Direct transcriptional targets distinguishing Bcl9l from Bcl9 were not defined"]},{"year":2011,"claim":"Transgenic BCL9L overexpression in APCMin/+ mice accelerated adenoma formation and progression, and gene expression analysis revealed BCL9L regulates both β-catenin-dependent and β-catenin-independent target genes.","evidence":"Transgenic mouse overexpression crossed with APCMin/+, siRNA knockdown, expression profiling","pmids":["21703997"],"confidence":"High","gaps":["Identity of the β-catenin-independent transcriptional partners not fully elucidated","Mechanism by which BCL9L accelerates tumor progression beyond gene expression changes not determined"]},{"year":2014,"claim":"Discovery that BCL9L regulates ERα transcription through Sp1 at the ESR1 promoter independent of β-catenin expanded its functional repertoire beyond Wnt signaling.","evidence":"Co-IP, ChIP, luciferase reporters, siRNA, transgenic mouse","pmids":["25149534"],"confidence":"Medium","gaps":["Whether BCL9L–Sp1 interaction is direct or bridged by additional factors is unresolved","Genome-wide scope of β-catenin-independent BCL9L transcriptional targets not mapped"]},{"year":2015,"claim":"WWOX was identified as a nuclear inhibitor of BCL9L-dependent Wnt transcription, acting through direct interaction with BCL9L to block β-catenin–TCF1 binding, with HDAC3 promoting this inhibitory complex independently of deacetylase activity.","evidence":"Co-IP, reporter assays, Xenopus secondary axis assay, confocal microscopy","pmids":["25678599"],"confidence":"Medium","gaps":["Physiological relevance of WWOX–BCL9L interaction in normal tissue or cancer progression not shown in vivo","Mechanism of deacetylase-independent HDAC3 scaffolding function not defined"]},{"year":2017,"claim":"BCL9L loss of function in colorectal cancer was shown to reduce basal caspase-2 levels, preventing MDM2 and BID cleavage and thereby enabling tolerance of chromosome missegregation and aneuploidy — a Wnt-independent tumor-suppressive function.","evidence":"Genomic analysis of CRC, cell line knockdown, xenograft models, caspase-2 activity and cleavage assays","pmids":["28073006"],"confidence":"High","gaps":["Transcriptional mechanism linking BCL9L to caspase-2 expression not identified","Whether this aneuploidy-tolerance pathway operates in tissues beyond the colon is unknown"]},{"year":2021,"claim":"Domain-specific mutagenesis in a breast cancer conditional knockout model established that the HD2–β-catenin interaction is the primary oncogenic interface of BCL9L, driving tumor growth and metastasis, whereas HD1–Pygopus binding contributes only moderately.","evidence":"Conditional double KO in MMTV-PyMT mice, domain-deletion and point mutagenesis (D164A), metastasis assays","pmids":["34545187"],"confidence":"High","gaps":["Whether HD2-independent functions (e.g., Sp1 or caspase-2 regulation) contribute to breast cancer phenotype not tested","Structural basis for differential importance of HD1 vs HD2 not resolved"]},{"year":2021,"claim":"BCL9/BCL9L was shown to suppress antitumor immunity in triple-negative breast cancer by limiting CD8⁺ T cell infiltration through both Wnt and TGF-β pathways, and pharmacological inhibition reversed this immune suppression.","evidence":"Genetic knockdown, pharmacological inhibitor hsBCL9CT-24, immune profiling, co-culture assays","pmids":["33767438"],"confidence":"Medium","gaps":["Whether immune modulation is cell-intrinsic to tumor cells or involves stromal BCL9L expression not separated","Relative contribution of Wnt versus TGF-β pathway to immune evasion not resolved"]},{"year":2024,"claim":"The immunomodulatory mechanism was refined to show that BCL9/BCL9L restrains cDC1 activation and tumor infiltration via the XCL1–XCR1 axis, and that its loss activates NF-κB/IRF1 signaling in dendritic cells to enhance antigen presentation and CD8⁺ T cell responses.","evidence":"Bcl9/Bcl9l KO mice, pharmacological inhibitor hsBCL9z96, single-cell transcriptomics, CD8⁺ T cell functional assays","pmids":["38811552"],"confidence":"Medium","gaps":["Whether BCL9L acts cell-autonomously within dendritic cells or via tumor-secreted factors remains unresolved","Applicability of immune mechanism to tumor types beyond breast cancer not tested"]},{"year":null,"claim":"Key open questions include the structural basis of BCL9L's multi-domain interactions, the transcriptional mechanism linking BCL9L to caspase-2 expression, whether BCL9L acts cell-autonomously in immune cells, and the genome-wide repertoire of β-catenin-independent BCL9L targets.","evidence":"","pmids":[],"confidence":"Low","gaps":["No high-resolution structure of BCL9L bound to β-catenin or Pygopus exists","Genome-wide identification of β-catenin-independent BCL9L target genes has not been performed","Cell-type-specific dissection of BCL9L function in immune versus tumor compartments is lacking"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,1,2,4,5]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,1,6]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,1,4,5]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[10,11]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[3,4,8,9]}],"complexes":["β-catenin–TCF–BCL9L–Pygopus transcriptional complex"],"partners":["CTNNB1","PYGO2","SP1","WWOX","HDAC3","BCL9"],"other_free_text":[]},"mechanistic_narrative":"BCL9L is a nuclear transcriptional co-activator that functions as a key component of the Wnt/β-catenin signaling cascade, bridging β-catenin–TCF complexes (via its HD2 domain) with Pygopus (via its HD1 domain) to drive transcription of target genes controlling epithelial-mesenchymal transition, intestinal stem cell maintenance, and tumor progression [PMID:15371335, PMID:20682801, PMID:34545187]. Beyond canonical Wnt signaling, BCL9L regulates estrogen receptor α transcription through a β-catenin-independent interaction with the transcription factor Sp1 and controls caspase-2 levels to enforce chromosome segregation fidelity and suppress aneuploidy tolerance [PMID:25149534, PMID:28073006]. BCL9L also shapes the tumor immune microenvironment by restraining conventional type 1 dendritic cell activation via the XCL1–XCR1/NF-κB/IRF1 axis and limiting CD8⁺ T cell infiltration, such that its inhibition enhances antitumor immunity [PMID:38811552, PMID:33767438]."},"prefetch_data":{"uniprot":{"accession":"Q86UU0","full_name":"B-cell CLL/lymphoma 9-like protein","aliases":["Protein BCL9-2"],"length_aa":1499,"mass_kda":157.1,"function":"Transcriptional regulator that acts as an activator. Promotes beta-catenin transcriptional activity. Plays a role in tumorigenesis. Enhances the neoplastic transforming activity of CTNNB1 (By similarity)","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q86UU0/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/BCL9L","classification":"Not Classified","n_dependent_lines":64,"n_total_lines":1208,"dependency_fraction":0.052980132450331126},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/BCL9L","total_profiled":1310},"omim":[{"mim_id":"609004","title":"B-CELL CLL/LYMPHOMA 9-LIKE; BCL9L","url":"https://www.omim.org/entry/609004"},{"mim_id":"116806","title":"CATENIN, BETA-1; CTNNB1","url":"https://www.omim.org/entry/116806"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Nucleoli fibrillar center","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/BCL9L"},"hgnc":{"alias_symbol":["DLNB11","B9L","Bcl9-2"],"prev_symbol":[]},"alphafold":{"accession":"Q86UU0","domains":[{"cath_id":"-","chopping":"241-273","consensus_level":"medium","plddt":87.4321,"start":241,"end":273}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q86UU0","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q86UU0-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q86UU0-F1-predicted_aligned_error_v6.png","plddt_mean":42.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=BCL9L","jax_strain_url":"https://www.jax.org/strain/search?query=BCL9L"},"sequence":{"accession":"Q86UU0","fasta_url":"https://rest.uniprot.org/uniprotkb/Q86UU0.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q86UU0/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q86UU0"}},"corpus_meta":[{"pmid":"15371335","id":"PMC_15371335","title":"Essential role of BCL9-2 in the switch between beta-catenin's adhesive and transcriptional functions.","date":"2004","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/15371335","citation_count":273,"is_preprint":false},{"pmid":"12964048","id":"PMC_12964048","title":"Identification and characterization of human BCL9L gene and mouse Bcl9l gene in silico.","date":"2003","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12964048","citation_count":114,"is_preprint":false},{"pmid":"20682801","id":"PMC_20682801","title":"Bcl9/Bcl9l are critical for Wnt-mediated regulation of stem cell traits in colon epithelium and adenocarcinomas.","date":"2010","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/20682801","citation_count":109,"is_preprint":false},{"pmid":"15574752","id":"PMC_15574752","title":"Role of a BCL9-related beta-catenin-binding protein, B9L, in tumorigenesis induced by aberrant activation of Wnt signaling.","date":"2004","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/15574752","citation_count":78,"is_preprint":false},{"pmid":"28073006","id":"PMC_28073006","title":"BCL9L Dysfunction Impairs Caspase-2 Expression Permitting Aneuploidy Tolerance in Colorectal Cancer.","date":"2017","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/28073006","citation_count":77,"is_preprint":false},{"pmid":"33436545","id":"PMC_33436545","title":"Long non-coding RNA LINC00665 promotes gemcitabine resistance of Cholangiocarcinoma cells via regulating EMT and stemness properties through miR-424-5p/BCL9L axis.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/33436545","citation_count":48,"is_preprint":false},{"pmid":"21703997","id":"PMC_21703997","title":"BCL9-2 promotes early stages of intestinal tumor progression.","date":"2011","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/21703997","citation_count":47,"is_preprint":false},{"pmid":"33535177","id":"PMC_33535177","title":"Matrix stiffness promotes glioma cell stemness by activating BCL9L/Wnt/β-catenin signaling.","date":"2021","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/33535177","citation_count":37,"is_preprint":false},{"pmid":"33767438","id":"PMC_33767438","title":"BCL9/BCL9L promotes tumorigenicity through immune-dependent and independent mechanisms in triple negative breast cancer.","date":"2021","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/33767438","citation_count":33,"is_preprint":false},{"pmid":"17113272","id":"PMC_17113272","title":"BCL9-2 binds Arm/beta-catenin in a Tyr142-independent manner and requires Pygopus for its function in Wg/Wnt signaling.","date":"2006","source":"Mechanisms of development","url":"https://pubmed.ncbi.nlm.nih.gov/17113272","citation_count":32,"is_preprint":false},{"pmid":"31440992","id":"PMC_31440992","title":"Wnt status-dependent oncogenic role of BCL9 and BCL9L in hepatocellular carcinoma.","date":"2019","source":"Hepatology international","url":"https://pubmed.ncbi.nlm.nih.gov/31440992","citation_count":30,"is_preprint":false},{"pmid":"27713160","id":"PMC_27713160","title":"Role of BCL9L in transforming growth factor-β (TGF-β)-induced epithelial-to-mesenchymal-transition (EMT) and metastasis of pancreatic cancer.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27713160","citation_count":26,"is_preprint":false},{"pmid":"30698996","id":"PMC_30698996","title":"miR-22 and miR-214 targeting BCL9L inhibit proliferation, metastasis, and epithelial-mesenchymal transition by down-regulating Wnt signaling in colon cancer.","date":"2019","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/30698996","citation_count":25,"is_preprint":false},{"pmid":"34545187","id":"PMC_34545187","title":"The interactions of Bcl9/Bcl9L with β-catenin and Pygopus promote breast cancer growth, invasion, and metastasis.","date":"2021","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/34545187","citation_count":24,"is_preprint":false},{"pmid":"33117820","id":"PMC_33117820","title":"miR-766-3p Targeting BCL9L Suppressed Tumorigenesis, Epithelial-Mesenchymal Transition, and Metastasis Through the β-Catenin Signaling Pathway in Osteosarcoma Cells.","date":"2020","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/33117820","citation_count":19,"is_preprint":false},{"pmid":"25149534","id":"PMC_25149534","title":"The BCL9-2 proto-oncogene governs estrogen receptor alpha expression in breast tumorigenesis.","date":"2014","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25149534","citation_count":19,"is_preprint":false},{"pmid":"38811552","id":"PMC_38811552","title":"Targeting BCL9/BCL9L enhances antigen presentation by promoting conventional type 1 dendritic cell (cDC1) activation and tumor infiltration.","date":"2024","source":"Signal transduction and targeted therapy","url":"https://pubmed.ncbi.nlm.nih.gov/38811552","citation_count":18,"is_preprint":false},{"pmid":"17309600","id":"PMC_17309600","title":"Immunohistochemical expression of the beta-catenin-interacting protein B9L is associated with histological high nuclear grade and immunohistochemical ErbB2/HER-2 expression in breast cancers.","date":"2007","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/17309600","citation_count":16,"is_preprint":false},{"pmid":"27539223","id":"PMC_27539223","title":"BCL9L expression in pancreatic neoplasia with a focus on SPN: a possible explanation for the enigma of the benign neoplasia.","date":"2016","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/27539223","citation_count":16,"is_preprint":false},{"pmid":"17129358","id":"PMC_17129358","title":"Up-regulation of a BCL9-related beta-catenin-binding protein, B9L, in different stages of sporadic colorectal adenoma.","date":"2007","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/17129358","citation_count":15,"is_preprint":false},{"pmid":"15703843","id":"PMC_15703843","title":"Identification and characterization of rat Bcl9l gene in silico.","date":"2005","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/15703843","citation_count":15,"is_preprint":false},{"pmid":"34319913","id":"PMC_34319913","title":"Type I collagen promotes tumor progression of integrin β1 positive gastric cancer through a BCL9L/β-catenin signaling pathway.","date":"2021","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/34319913","citation_count":15,"is_preprint":false},{"pmid":"35628130","id":"PMC_35628130","title":"Wnt/β-Catenin Signalling and Its Cofactor BCL9L Have an Oncogenic Effect in Bladder Cancer Cells.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35628130","citation_count":14,"is_preprint":false},{"pmid":"25678599","id":"PMC_25678599","title":"The Tumor-Suppressor WWOX and HDAC3 Inhibit the Transcriptional Activity of the β-Catenin Coactivator BCL9-2 in Breast Cancer Cells.","date":"2015","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/25678599","citation_count":13,"is_preprint":false},{"pmid":"38033858","id":"PMC_38033858","title":"Corrigendum: miR-766-3p targeting BCL9L suppressed tumorigenesis, epithelial-mesenchymal transition, and metastasis through the β-catenin signaling pathway in osteosarcoma cells.","date":"2023","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/38033858","citation_count":1,"is_preprint":false},{"pmid":"41800265","id":"PMC_41800265","title":"CD44/POU2F2/BCL9L axis mediates MIF-driven SPP1+TAM activation in colorectal cancer metastasis.","date":"2026","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/41800265","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":14601,"output_tokens":2855,"usd":0.043314},"stage2":{"model":"claude-opus-4-6","input_tokens":6328,"output_tokens":5744,"usd":0.26286},"total_usd":0.306174,"stage1_batch_id":"msgbatch_01TqNM6p6FsoMBT2jzQTwKBr","stage2_batch_id":"msgbatch_01Ya473eco8sTHbvRymQaU8o","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2004,\n      \"finding\": \"BCL9-2 (BCL9L) binds β-catenin and promotes nuclear β-catenin-dependent transcription, inducing epithelial-mesenchymal transition; this binding is modulated by phosphorylation of Tyr142 of β-catenin, which favors BCL9-2 binding and precludes interaction with α-catenin, thereby switching β-catenin from adhesive to transcriptional functions.\",\n      \"method\": \"RNA interference, co-immunoprecipitation, reporter assays, zebrafish epistasis (Wnt8 pathway), in vivo EMT assays\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (RNAi, Co-IP, in vivo epistasis), highly cited foundational paper\",\n      \"pmids\": [\"15371335\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"BCL9L (B9L) interacts with the β-catenin–TCF complex and enhances its transactivation potential; B9L is required for elevated β-catenin–TCF-mediated transcription in colorectal tumor cells and for β-catenin-induced cellular transformation.\",\n      \"method\": \"Co-immunoprecipitation, luciferase reporter assays, siRNA knockdown, RK3E transformation assay\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP plus functional reporter and transformation assays\",\n      \"pmids\": [\"15574752\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"BCL9-2 functionally replaces Drosophila Legless in Wg/Wnt signaling both in cultured mammalian cells and in vivo in Drosophila; this rescue activity requires the ability of BCL9-2 to bind Pygopus via its HD1 domain, and Tyr142 phosphorylation of β-catenin is not required for BCL9-2 binding or transcriptional activity.\",\n      \"method\": \"Drosophila genetic rescue assays, mammalian cell reporter assays, site-directed mutagenesis of Tyr142\",\n      \"journal\": \"Mechanisms of development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — mutagenesis combined with in vivo genetic rescue across two systems\",\n      \"pmids\": [\"17113272\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Conditional ablation of both Bcl9 and Bcl9l in mouse intestinal epithelium decreases expression of intestinal stem cell markers, impairs colon epithelium regeneration, and abolishes EMT and stem cell-like properties in adenocarcinomas, establishing Bcl9/Bcl9l as essential mediators of a Wnt-dependent subset of target genes controlling EMT and stemness.\",\n      \"method\": \"Conditional knockout mouse model, transcriptional profiling, immunohistochemistry, stem cell marker analysis\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean conditional KO with defined cellular and transcriptional phenotype, replicated with Bcl9/Bcl9l double ablation\",\n      \"pmids\": [\"20682801\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"BCL9-2 regulates expression of both β-catenin-dependent and β-catenin-independent target genes in intestinal epithelia; transgenic overexpression of BCL9-2 in the intestine of APCMin/+ mice accelerates adenoma formation and progression to invasive tumors.\",\n      \"method\": \"siRNA knockdown, transgenic mouse overexpression crossed with APCMin/+, gene expression analysis\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo transgenic model with tumor phenotype plus siRNA mechanistic data\",\n      \"pmids\": [\"21703997\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"BCL9-2 regulates estrogen receptor alpha (ERα) transcription independently of β-catenin by interacting with the transcription factor Sp1 at the proximal ESR1 gene promoter.\",\n      \"method\": \"Co-immunoprecipitation, chromatin immunoprecipitation, luciferase reporter assays, siRNA knockdown, transgenic mouse model\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP plus ChIP plus reporter assays in single lab\",\n      \"pmids\": [\"25149534\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"WWOX interacts with BCL9-2 in the nucleus (co-localizing with β-catenin) and inhibits BCL9-2-dependent Wnt/β-catenin transcriptional activity by blocking the β-catenin–TCF1 interaction; HDAC3 associates with BCL9-2, promotes the WWOX–BCL9-2 interaction independently of its deacetylase activity, and enhances WWOX-mediated inhibition of BCL9-2.\",\n      \"method\": \"Co-immunoprecipitation, luciferase reporter assays, Xenopus secondary axis assay, confocal co-localization\",\n      \"journal\": \"Molecular cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (Co-IP, reporter, Xenopus in vivo assay) from single lab\",\n      \"pmids\": [\"25678599\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"BCL9L knockdown in pancreatic cancer cells induces an epithelial phenotype (increased E-cadherin, membrane retention of β-catenin), impairs proliferation, migration and invasion, and significantly reduces liver metastasis in xenograft mouse models; BCL9L depletion prevents TGF-β-induced EMT.\",\n      \"method\": \"RNAi knockdown, xenograft mouse model, cell migration/invasion assays, immunofluorescence\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KD with multiple cellular phenotype readouts plus in vivo xenograft\",\n      \"pmids\": [\"27713160\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"BCL9L loss-of-function (LOH and mutations in CRC) reduces basal caspase-2 levels and prevents caspase-2-mediated cleavage of MDM2 and BID, thereby promoting tolerance of chromosome missegregation events and aneuploidy propagation; this occurs independently of TP53 status.\",\n      \"method\": \"Genomic analysis of CRC, cell line knockdown, xenograft models, caspase-2 activity assays, protein cleavage assays\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple functional assays (caspase cleavage, in vivo xenograft, CIN phenotype) in a single rigorous study\",\n      \"pmids\": [\"28073006\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Conditional double knockout of Bcl9 and Bcl9l in the MMTV-PyMT breast cancer mouse model causes tumor cell death; disruption of the Bcl9/Bcl9l HD2 domain interaction with β-catenin (or the β-catenin D164A point mutation) reduces primary tumor growth, proliferation, invasion and lung metastasis; disruption of HD1-mediated binding to Pygopus has only moderate effects.\",\n      \"method\": \"Conditional knockout mouse model, domain-deletion mutants, point mutagenesis (D164A), tumor growth and metastasis assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — domain-specific mutagenesis combined with in vivo conditional KO and metastasis readouts\",\n      \"pmids\": [\"34545187\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"BCL9/BCL9L promotes tumorigenicity in TNBC through both Wnt and TGF-β pathways; BCL9/BCL9L inhibits infiltration of CD8+ T cells in the tumor microenvironment, and pharmacological inhibition with hsBCL9CT-24 promotes cytotoxic T cell infiltration and reduces Treg cells.\",\n      \"method\": \"Genetic knockdown, pharmacological inhibitor, tumor microenvironment immune profiling, co-culture assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KD plus pharmacological inhibition with defined immune phenotype, single lab\",\n      \"pmids\": [\"33767438\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Targeting BCL9/BCL9L (pharmacological inhibitor hsBCL9z96 or genetic knockout) promotes antigen presentation in tumors by increasing conventional type 1 dendritic cell (cDC1) activation and tumor infiltration via the XCL1–XCR1 axis; Bcl9/Bcl9l-deficient cDC1 show superior antigen presentation through NF-κB/IRF1 signaling.\",\n      \"method\": \"Bcl9/Bcl9l knockout mice, pharmacological inhibitor, single-cell transcriptomics, CD8+ T cell functional assays\",\n      \"journal\": \"Signal transduction and targeted therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KO mouse plus pharmacological inhibition plus scRNA-seq mechanistic pathway identification\",\n      \"pmids\": [\"38811552\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"BCL9L (BCL9-2/B9L) is a nuclear transcriptional co-activator that binds β-catenin (via its HD2 domain, enhanced by Tyr142 phosphorylation of β-catenin) and Pygopus (via its HD1 domain) to amplify Wnt/β-catenin target gene transcription, promotes epithelial-to-mesenchymal transition and intestinal stem cell maintenance, regulates ERα transcription independently of β-catenin through Sp1 interaction, controls caspase-2 levels to modulate aneuploidy tolerance, and shapes antitumor immunity by restraining cDC1 activation and CD8+ T cell infiltration.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"BCL9L is a nuclear transcriptional co-activator that functions as a key component of the Wnt/β-catenin signaling cascade, bridging β-catenin–TCF complexes (via its HD2 domain) with Pygopus (via its HD1 domain) to drive transcription of target genes controlling epithelial-mesenchymal transition, intestinal stem cell maintenance, and tumor progression [PMID:15371335, PMID:20682801, PMID:34545187]. Beyond canonical Wnt signaling, BCL9L regulates estrogen receptor α transcription through a β-catenin-independent interaction with the transcription factor Sp1 and controls caspase-2 levels to enforce chromosome segregation fidelity and suppress aneuploidy tolerance [PMID:25149534, PMID:28073006]. BCL9L also shapes the tumor immune microenvironment by restraining conventional type 1 dendritic cell activation via the XCL1–XCR1/NF-κB/IRF1 axis and limiting CD8⁺ T cell infiltration, such that its inhibition enhances antitumor immunity [PMID:38811552, PMID:33767438].\",\n  \"teleology\": [\n    {\n      \"year\": 2004,\n      \"claim\": \"Identification of BCL9L as a β-catenin-binding co-activator established its role in Wnt-dependent transcription and revealed that Tyr142 phosphorylation of β-catenin switches it from adhesive to transcriptional functions by favoring BCL9L recruitment.\",\n      \"evidence\": \"Co-IP, RNAi, reporter assays, and zebrafish Wnt8 epistasis in mammalian cells and zebrafish\",\n      \"pmids\": [\"15371335\", \"15574752\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether Tyr142 phosphorylation is required for BCL9L binding was subsequently contested\",\n        \"Relative contributions of BCL9L versus BCL9 were not delineated\"\n      ]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Cross-species rescue showed BCL9L functionally replaces Drosophila Legless in Wg/Wnt signaling and that HD1-mediated Pygopus binding is essential, while Tyr142 phosphorylation of β-catenin proved dispensable for BCL9L activity.\",\n      \"evidence\": \"Drosophila genetic rescue, mammalian reporter assays, Tyr142 site-directed mutagenesis\",\n      \"pmids\": [\"17113272\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Structural basis of HD1–Pygopus and HD2–β-catenin interfaces not resolved\",\n        \"In vivo mammalian requirement for BCL9L not yet tested\"\n      ]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Conditional ablation of Bcl9 and Bcl9l in mouse intestinal epithelium demonstrated their non-redundant requirement for intestinal stem cell gene expression, colon regeneration, and EMT/stemness in adenocarcinomas.\",\n      \"evidence\": \"Conditional double knockout mouse, transcriptional profiling, immunohistochemistry\",\n      \"pmids\": [\"20682801\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Individual contribution of Bcl9l versus Bcl9 in the intestine not separated\",\n        \"Direct transcriptional targets distinguishing Bcl9l from Bcl9 were not defined\"\n      ]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Transgenic BCL9L overexpression in APCMin/+ mice accelerated adenoma formation and progression, and gene expression analysis revealed BCL9L regulates both β-catenin-dependent and β-catenin-independent target genes.\",\n      \"evidence\": \"Transgenic mouse overexpression crossed with APCMin/+, siRNA knockdown, expression profiling\",\n      \"pmids\": [\"21703997\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Identity of the β-catenin-independent transcriptional partners not fully elucidated\",\n        \"Mechanism by which BCL9L accelerates tumor progression beyond gene expression changes not determined\"\n      ]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Discovery that BCL9L regulates ERα transcription through Sp1 at the ESR1 promoter independent of β-catenin expanded its functional repertoire beyond Wnt signaling.\",\n      \"evidence\": \"Co-IP, ChIP, luciferase reporters, siRNA, transgenic mouse\",\n      \"pmids\": [\"25149534\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether BCL9L–Sp1 interaction is direct or bridged by additional factors is unresolved\",\n        \"Genome-wide scope of β-catenin-independent BCL9L transcriptional targets not mapped\"\n      ]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"WWOX was identified as a nuclear inhibitor of BCL9L-dependent Wnt transcription, acting through direct interaction with BCL9L to block β-catenin–TCF1 binding, with HDAC3 promoting this inhibitory complex independently of deacetylase activity.\",\n      \"evidence\": \"Co-IP, reporter assays, Xenopus secondary axis assay, confocal microscopy\",\n      \"pmids\": [\"25678599\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Physiological relevance of WWOX–BCL9L interaction in normal tissue or cancer progression not shown in vivo\",\n        \"Mechanism of deacetylase-independent HDAC3 scaffolding function not defined\"\n      ]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"BCL9L loss of function in colorectal cancer was shown to reduce basal caspase-2 levels, preventing MDM2 and BID cleavage and thereby enabling tolerance of chromosome missegregation and aneuploidy — a Wnt-independent tumor-suppressive function.\",\n      \"evidence\": \"Genomic analysis of CRC, cell line knockdown, xenograft models, caspase-2 activity and cleavage assays\",\n      \"pmids\": [\"28073006\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Transcriptional mechanism linking BCL9L to caspase-2 expression not identified\",\n        \"Whether this aneuploidy-tolerance pathway operates in tissues beyond the colon is unknown\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Domain-specific mutagenesis in a breast cancer conditional knockout model established that the HD2–β-catenin interaction is the primary oncogenic interface of BCL9L, driving tumor growth and metastasis, whereas HD1–Pygopus binding contributes only moderately.\",\n      \"evidence\": \"Conditional double KO in MMTV-PyMT mice, domain-deletion and point mutagenesis (D164A), metastasis assays\",\n      \"pmids\": [\"34545187\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether HD2-independent functions (e.g., Sp1 or caspase-2 regulation) contribute to breast cancer phenotype not tested\",\n        \"Structural basis for differential importance of HD1 vs HD2 not resolved\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"BCL9/BCL9L was shown to suppress antitumor immunity in triple-negative breast cancer by limiting CD8⁺ T cell infiltration through both Wnt and TGF-β pathways, and pharmacological inhibition reversed this immune suppression.\",\n      \"evidence\": \"Genetic knockdown, pharmacological inhibitor hsBCL9CT-24, immune profiling, co-culture assays\",\n      \"pmids\": [\"33767438\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether immune modulation is cell-intrinsic to tumor cells or involves stromal BCL9L expression not separated\",\n        \"Relative contribution of Wnt versus TGF-β pathway to immune evasion not resolved\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"The immunomodulatory mechanism was refined to show that BCL9/BCL9L restrains cDC1 activation and tumor infiltration via the XCL1–XCR1 axis, and that its loss activates NF-κB/IRF1 signaling in dendritic cells to enhance antigen presentation and CD8⁺ T cell responses.\",\n      \"evidence\": \"Bcl9/Bcl9l KO mice, pharmacological inhibitor hsBCL9z96, single-cell transcriptomics, CD8⁺ T cell functional assays\",\n      \"pmids\": [\"38811552\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether BCL9L acts cell-autonomously within dendritic cells or via tumor-secreted factors remains unresolved\",\n        \"Applicability of immune mechanism to tumor types beyond breast cancer not tested\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key open questions include the structural basis of BCL9L's multi-domain interactions, the transcriptional mechanism linking BCL9L to caspase-2 expression, whether BCL9L acts cell-autonomously in immune cells, and the genome-wide repertoire of β-catenin-independent BCL9L targets.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No high-resolution structure of BCL9L bound to β-catenin or Pygopus exists\",\n        \"Genome-wide identification of β-catenin-independent BCL9L target genes has not been performed\",\n        \"Cell-type-specific dissection of BCL9L function in immune versus tumor compartments is lacking\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 1, 2, 4, 5]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 1, 6]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0162582\", \"supporting_discovery_ids\": [0, 1, 2, 3, 4, 6, 9]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 1, 4, 5]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [10, 11]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [3, 4, 8, 9]}\n    ],\n    \"complexes\": [\n      \"β-catenin–TCF–BCL9L–Pygopus transcriptional complex\"\n    ],\n    \"partners\": [\n      \"CTNNB1\",\n      \"PYGO2\",\n      \"SP1\",\n      \"WWOX\",\n      \"HDAC3\",\n      \"BCL9\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\nWait, I need to fix the pathway term_id. \"GO:0162582\" is not valid — that should be \"R-HSA-162582\" for Signal Transduction. Let me correct:\n\n```json\n{\n  \"mechanistic_narrative\": \"BCL9L is a nuclear transcriptional co-activator that functions as a key component of the Wnt/β-catenin signaling cascade, bridging β-catenin–TCF complexes (via its HD2 domain) with Pygopus (via its HD1 domain) to drive transcription of target genes controlling epithelial-mesenchymal transition, intestinal stem cell maintenance, and tumor progression [PMID:15371335, PMID:20682801, PMID:34545187]. Beyond canonical Wnt signaling, BCL9L regulates estrogen receptor α transcription through a β-catenin-independent interaction with the transcription factor Sp1 and controls caspase-2 levels to enforce chromosome segregation fidelity and suppress aneuploidy tolerance [PMID:25149534, PMID:28073006]. BCL9L also shapes the tumor immune microenvironment by restraining conventional type 1 dendritic cell activation via the XCL1–XCR1/NF-κB/IRF1 axis and limiting CD8⁺ T cell infiltration, such that its inhibition enhances antitumor immunity [PMID:38811552, PMID:33767438].\",\n  \"teleology\": [\n    {\n      \"year\": 2004,\n      \"claim\": \"Identification of BCL9L as a β-catenin-binding co-activator established its role in Wnt-dependent transcription and revealed that Tyr142 phosphorylation of β-catenin switches it from adhesive to transcriptional functions by favoring BCL9L recruitment.\",\n      \"evidence\": \"Co-IP, RNAi, reporter assays, and zebrafish Wnt8 epistasis in mammalian cells and zebrafish\",\n      \"pmids\": [\"15371335\", \"15574752\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether Tyr142 phosphorylation is required for BCL9L binding was subsequently contested\",\n        \"Relative contributions of BCL9L versus BCL9 were not delineated\"\n      ]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Cross-species rescue showed BCL9L functionally replaces Drosophila Legless in Wg/Wnt signaling and that HD1-mediated Pygopus binding is essential, while Tyr142 phosphorylation of β-catenin proved dispensable for BCL9L activity.\",\n      \"evidence\": \"Drosophila genetic rescue, mammalian reporter assays, Tyr142 site-directed mutagenesis\",\n      \"pmids\": [\"17113272\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Structural basis of HD1–Pygopus and HD2–β-catenin interfaces not resolved\",\n        \"In vivo mammalian requirement for BCL9L not yet tested\"\n      ]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Conditional ablation of Bcl9 and Bcl9l in mouse intestinal epithelium demonstrated their non-redundant requirement for intestinal stem cell gene expression, colon regeneration, and EMT/stemness in adenocarcinomas.\",\n      \"evidence\": \"Conditional double knockout mouse, transcriptional profiling, immunohistochemistry\",\n      \"pmids\": [\"20682801\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Individual contribution of Bcl9l versus Bcl9 in the intestine not separated\",\n        \"Direct transcriptional targets distinguishing Bcl9l from Bcl9 were not defined\"\n      ]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Transgenic BCL9L overexpression in APCMin/+ mice accelerated adenoma formation and progression, and gene expression analysis revealed BCL9L regulates both β-catenin-dependent and β-catenin-independent target genes.\",\n      \"evidence\": \"Transgenic mouse overexpression crossed with APCMin/+, siRNA knockdown, expression profiling\",\n      \"pmids\": [\"21703997\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Identity of the β-catenin-independent transcriptional partners not fully elucidated\",\n        \"Mechanism by which BCL9L accelerates tumor progression beyond gene expression changes not determined\"\n      ]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Discovery that BCL9L regulates ERα transcription through Sp1 at the ESR1 promoter independent of β-catenin expanded its functional repertoire beyond Wnt signaling.\",\n      \"evidence\": \"Co-IP, ChIP, luciferase reporters, siRNA, transgenic mouse\",\n      \"pmids\": [\"25149534\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether BCL9L–Sp1 interaction is direct or bridged by additional factors is unresolved\",\n        \"Genome-wide scope of β-catenin-independent BCL9L transcriptional targets not mapped\"\n      ]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"WWOX was identified as a nuclear inhibitor of BCL9L-dependent Wnt transcription, acting through direct interaction with BCL9L to block β-catenin–TCF1 binding, with HDAC3 promoting this inhibitory complex independently of deacetylase activity.\",\n      \"evidence\": \"Co-IP, reporter assays, Xenopus secondary axis assay, confocal microscopy\",\n      \"pmids\": [\"25678599\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Physiological relevance of WWOX–BCL9L interaction in normal tissue or cancer progression not shown in vivo\",\n        \"Mechanism of deacetylase-independent HDAC3 scaffolding function not defined\"\n      ]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"BCL9L loss of function in colorectal cancer was shown to reduce basal caspase-2 levels, preventing MDM2 and BID cleavage and thereby enabling tolerance of chromosome missegregation and aneuploidy — a Wnt-independent tumor-suppressive function.\",\n      \"evidence\": \"Genomic analysis of CRC, cell line knockdown, xenograft models, caspase-2 activity and cleavage assays\",\n      \"pmids\": [\"28073006\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Transcriptional mechanism linking BCL9L to caspase-2 expression not identified\",\n        \"Whether this aneuploidy-tolerance pathway operates in tissues beyond the colon is unknown\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Domain-specific mutagenesis in a breast cancer conditional knockout model established that the HD2–β-catenin interaction is the primary oncogenic interface of BCL9L, driving tumor growth and metastasis, whereas HD1–Pygopus binding contributes only moderately.\",\n      \"evidence\": \"Conditional double KO in MMTV-PyMT mice, domain-deletion and point mutagenesis (D164A), metastasis assays\",\n      \"pmids\": [\"34545187\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether HD2-independent functions (e.g., Sp1 or caspase-2 regulation) contribute to breast cancer phenotype not tested\",\n        \"Structural basis for differential importance of HD1 vs HD2 not resolved\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"BCL9/BCL9L was shown to suppress antitumor immunity in triple-negative breast cancer by limiting CD8⁺ T cell infiltration through both Wnt and TGF-β pathways, and pharmacological inhibition reversed this immune suppression.\",\n      \"evidence\": \"Genetic knockdown, pharmacological inhibitor hsBCL9CT-24, immune profiling, co-culture assays\",\n      \"pmids\": [\"33767438\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether immune modulation is cell-intrinsic to tumor cells or involves stromal BCL9L expression not separated\",\n        \"Relative contribution of Wnt versus TGF-β pathway to immune evasion not resolved\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"The immunomodulatory mechanism was refined to show that BCL9/BCL9L restrains cDC1 activation and tumor infiltration via the XCL1–XCR1 axis, and that its loss activates NF-κB/IRF1 signaling in dendritic cells to enhance antigen presentation and CD8⁺ T cell responses.\",\n      \"evidence\": \"Bcl9/Bcl9l KO mice, pharmacological inhibitor hsBCL9z96, single-cell transcriptomics, CD8⁺ T cell functional assays\",\n      \"pmids\": [\"38811552\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether BCL9L acts cell-autonomously within dendritic cells or via tumor-secreted factors remains unresolved\",\n        \"Applicability of immune mechanism to tumor types beyond breast cancer not tested\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key open questions include the structural basis of BCL9L's multi-domain interactions, the transcriptional mechanism linking BCL9L to caspase-2 expression, whether BCL9L acts cell-autonomously in immune cells, and the genome-wide repertoire of β-catenin-independent BCL9L targets.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No high-resolution structure of BCL9L bound to β-catenin or Pygopus exists\",\n        \"Genome-wide identification of β-catenin-independent BCL9L target genes has not been performed\",\n        \"Cell-type-specific dissection of BCL9L function in immune versus tumor compartments is lacking\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 1, 2, 4, 5]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 1, 6]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 2, 3, 4, 6, 9]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 1, 4, 5]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [10, 11]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [3, 4, 8, 9]}\n    ],\n    \"complexes\": [\n      \"β-catenin–TCF–BCL9L–Pygopus transcriptional complex\"\n    ],\n    \"partners\": [\n      \"CTNNB1\",\n      \"PYGO2\",\n      \"SP1\",\n      \"WWOX\",\n      \"HDAC3\",\n      \"BCL9\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}